Immunomic TherapeuticsImmunomic Therapeutics
Immunomic TherapeuticsImmunomic Therapeutics
  • Pipeline
  • Partnerships
  • Clinical Trials
    • ITI-1000: Glioblastoma Multiforme
    • ITI-1001: Glioblastoma Multiforme
    • ITI-3000: Merkel Cell Carcinoma
  • Team
  • Careers
  • Media
  • Contact Us
  • Pipeline
  • Partnerships
  • Clinical Trials
    • ITI-1000: Glioblastoma Multiforme
    • ITI-1001: Glioblastoma Multiforme
    • ITI-3000: Merkel Cell Carcinoma
  • Team
  • Careers
  • Media
  • Contact Us

Blog

  • Articles
  • Blog
  • Events
  • Featured
  • Highlights
  • Posters
  • Press
  • Press Releases
  • Uncategorized

Immunomic Therapeutics To Present at BIO-Europe Annual Conference

by Sara Solt in Press Releases
Hershey, PA, & Rockville, MD – March 9, 2015 – Immunomic Therapeutics, Inc., (“ITI”) a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces it will ...
Read More

Immunomic Therapeutics, Inc. Appoints Vice President of Operations

by Sara Solt in Press Releases
HERSHEY, PA & ROCKVILLE, MD (PRWEB) FEBRUARY 10, 2015 Immunomic Therapeutics, Inc. (ITI) announced today that Timothy Coleman Ph.D. has joined the company to further develop a comprehensive growth plan and ...
Read More

Astellas Pharma and Immunomic Therapeutics Announce Exclusive License for JRC2-LAMP-vax, a Vaccine for Japanese Red Cedar Pollinosis

by Sara Solt in Press Releases
HERSHEY, Pa., Rockville, Md. and TOKYO, Jan. 29, 2015 /PRNewswire/ -- Immunomic Therapeutics, Inc. ("Immunomic Therapeutics"), a company developing next-generation vaccines based on the LAMP-vax platform, and Astellas Pharma Inc. ("Astellas") today announced they have entered into ...
Read More

Immunomic Therapeutics, Inc., To Present at Biotech Showcase™ 2015

by Sara Solt in Press Releases
HERSHEY, PA AND SAN FRANCISCO, CA (PRWEB) JANUARY 09, 2015 Immunomic Therapeutics, Inc., (ITI), a pioneering vaccine company, announced today that Dr. William Hearl, the Company’s President and CEO, will be ...
Read More

Immunomic Therapeutics Announces Successful Completion of Series A Preferred Stock Financing Round

by Sara Solt in Press Releases
HERSHEY, PA & ROCKVILLE, MD (PRWEB) OCTOBER 28, 2014 Immunomic Therapeutics, Inc.(ITI), a vaccine pioneer in the biotechnology industry, today announced the successful completion of a $6.8 million Series A preferred ...
Read More

The Next Generation of DNA Vaccines Is Poised to Transform the Healthcare Landscape

by Sara Solt in Articles
The Next Generation of DNA Vaccines Is Poised to Transform the Healthcare Landscape By Teri Heiland October 13, 2014 | Contributed Commentary | Over the last several decades, the advent of biotechnology has ...
Read More
1
23456789101112131415161718192021
…2223242526
← Previous page

Content
  • Pipeline
  • Partnerships
  • Team
  • Media
  • Contact Us
Careers
  • Careers
  • Compensation & Benefits
  • Culture & Beliefs
Policies
  • Expanded Access Policy
  • Privacy Policy
Social
  • Facebook
  • X / Twitter
  • Youtube
Telephone

+1.301.968.3501

Address

15010 Broschart Road

Rockville, MD 20850

© 2020 Immunomic Therapeutics, Inc. All Rights Reserved.